CD163 and glioblastoma: Immunohistochemical staining in matched paired tumor tissues from primary and corresponding progressive glioblastoma from our center indicated that the relevant targets of the anti-CSF1R and anti-PD1 combination regimen, i.e., CSF1R, the macrophage markers CD204, CD163, and PD1 and PD-L1, were present in patient-derived tissue of newly diagnosed and progressive disease (as illustrated in Figure 1, Supplementary Table S2).